Is AIM ImmunoTech Inc. (AIM) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 100.4% / 30% | 135.7% / 30% | 0.0% / 30% | 3054.12% / 5% | ✗ NOT HALAL |
| DJIM | 100.4% / 33% | 135.7% / 33% | 0.0% / 33% | 3054.12% / 5% | ✗ NOT HALAL |
| MSCI | 34.2% / 33% | 46.2% / 33% | 0.0% / 33% | 3054.12% / 5% | ✗ NOT HALAL |
| S&P | 100.4% / 33% | 135.7% / 33% | 0.0% / 33% | 3054.12% / 5% | ✗ NOT HALAL |
| FTSE | 34.2% / 33% | 46.2% / 33% | 0.0% / 50% | 3054.12% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 15.2% | |
| Operating Margin | -9411.5% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -95.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$15M |
| Free Cash Flow | -$15M |
| Total Debt | $3M |
| Current Ratio | 0.6 |
| Total Assets | $9M |
Price & Trading
| Last Close | $0.69 |
| 50-Day MA | $0.97 |
| 200-Day MA | $2.82 |
| Avg Volume | 4.7M |
| Beta | 1.2 |
|
52-Week Range
$0.61
| |
About AIM ImmunoTech Inc. (AIM)
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is AIM ImmunoTech Inc. (AIM) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), AIM ImmunoTech Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is AIM ImmunoTech Inc.'s debt ratio?
AIM ImmunoTech Inc.'s debt ratio is 100.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 34.2%.
What are AIM ImmunoTech Inc.'s key financial metrics?
AIM ImmunoTech Inc. has a market capitalization of $3M, and revenue of $170,000.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.